FDA accepts Shire’s BLA and grants priority review for Lanadelumab for Prevention of HAE
Shire announced the FDA accepted the BLA and granted priority review for lanadelumab (SHP643). Lanadelumab is an investigational treatment being evaluated for prevention of angioedema attacks in patients 12 years and older with the rare, genetic disorder, hereditary angioedema. February 23, 2018